抗心律失常药物与新发房颤患者晕厥及起搏器植入的关联
基于韩国国民健康保险系统2013至2019年新发房颤数据,共识别770977例新发房颤患者,其中142141例在诊断后1年内处方抗心律失常药物。多因素校正后,AAD使用与起搏器植入或晕厥风险增加3.5倍、晕厥2.0倍、起搏器植入5.0倍相关,倾向评分匹配分析结果一致,女性更易受影响。
要点
- 新发房颤早期节律控制使用AAD与起搏器植入或晕厥风险增加相关。
- 多因素校正后起搏器植入或晕厥风险增加3.5倍,起搏器植入单独增加5.0倍。
- 女性对AAD不良效应更易感,处方前应精确评估风险。
核心结论
- AAD使用与新发房颤患者起搏器植入或晕厥风险增加相关,且在各亚组中一致。
- 女性比男性更易受AAD不良效应影响。
研究设计与样本
- 基于韩国国民健康保险服务系统的数据,筛查2013至2019年所有新发房颤诊断。
- 识别房颤诊断后1年内处方AAD的患者,比较AAD使用者与非使用者的起搏器植入或晕厥风险。
- 共识别770977例新发房颤病例,其中142141例处方AAD。
主要发现
- 多因素校正后,AAD使用与起搏器植入或晕厥风险增加3.5倍相关。
- 多因素校正后,AAD使用与晕厥风险增加2.0倍相关。
- 多因素校正后,AAD使用与起搏器植入风险增加5.0倍相关。
- 倾向评分匹配分析显示类似结果,AAD使用与起搏器植入或晕厥风险显著相关。
- 该关联在各亚组中一致,女性比男性更易感。
临床怎么用
- 处方AAD前应精确评估起搏器植入或晕厥风险。
- 对女性患者使用AAD时应更加关注不良效应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early rhythm control therapy mainly with antiarrhythmic drugs (AADs) for new-onset atrial fibrillation (AF) reduces major adverse cardiovascular events. However, negative dromotropic effects of AADs via ion channel blocking may cause bradyarrhythmias. OBJECTIVES: This study aimed to evaluate the association between AAD use and the risk of pacemaker implantation or syncope in patients with new-onset AF receiving early rhythm control therapy with AADs. METHODS: This study was based on data from the Korean National Health Insurance Service system. We screened all new-onset AF diagnoses that occurred from 2013 to 2019 and identified patients who were prescribed AADs within 1 year of AF diagnosis. The risk of pacemaker implantation or syncope was compared between AAD users and nonusers. RESULTS: A total of 770,977 new-onset AF cases were identified and 142,141 patients were prescribed AADs. After multivariate adjustment, use of AADs was associated with 3.5-, 2.0-, and 5.0-fold increased risk of pacemaker implantation or syncope, syncope, and pacemaker implantation, respectively. Propensity score-matched analysis revealed similar results, demonstrating a significant association between AAD use and the risk of pacemaker implantation or syncope. This association was consistent across various subgroups. Women were more susceptible to adverse effects of AADs than men. CONCLUSIONS: This study showed an association between AADs and risk of pacemaker implantation or syncope, a consistent finding across various subgroups. Precise evaluation of such risk should be undertaken before prescription of AADs.
引用
- Kim YG, Lee HS, Kim H, et al. Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2024. PMID: 38479951. doi:10.1016/j.jacc.2024.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。